CD8A and neoplasm: Importantly, CD3 bsAb therapy with adjuvants alone did not improve tumor control in “cold” tumors, highlighting the necessity of an immunogenic antigen to generate substantial CD8 T-cell expansion and influx, resulting in significant survival benefits.